The ventricular assist devices market was valued at $1.6 billion in 2023 and is estimated to reach $4.1 billion by 2035, exhibiting a CAGR of 8.1% from 2024 to 2035. Ventricular assist device (VAD), also known as mechanical circulatory support (MCS) device, supports the pumping function of the heart. It is used to increase the amount of blood that flows through the patient’s body. It enables a patient with advanced heart failure to lead an improved quality of life once again. A ventricular assist device (VAD) helps in supporting either the right or the left ventricle, however, it is mostly implanted in the left ventricle. When placed in the left ventricle, it is called a left ventricular assist device (LVAD).
Increase in incidences of heart failures is the major factor driving the growth of ventricular assist devices market. There is increase in heart failure cases around the globe owing to various factors such as high prevalence of chronic conditions such as hypertension, diabetes, and obesity. Moreover, factors such as poor lifestyle choices and environmental pollution along with increased stress levels contribute to increase in the number of heart failure cases. For instance, according to an article published by Centers for Diseases Control and Prevention (CDC), in January 2023, heart disease is the leading cause of death for both men and women in the U.S. and about 6.2 million adults in the U.S. have heart failure. Thus, high incidences of heart failure increases the demand for ventricular assist devices around the globe and thus propels the growth of the market.
In addition, one of the major driving factors of the global ventricular assist devices market is the high prevalence of conditions such as diabetes, atherosclerosis, strokes, hypertension, and other chronic disorders. These conditions mainly arise due to change in lifestyle habits, unhealthy dietary habits, lack of physical activity, and smoking. This further raises the chances of heart failure in the patient and thus increases the demand for ventricular assist devices. Hence, such factors are expected to boost the growth of the market.
The global ventricular assist devices market is segmented into product, application, design, age, and region. By product, the market is categorized into left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs). On the basis of application, the market is fragmented into bridge-to-transplant (BTT), destination therapy, bridge-to-recovery (BTR), and bridge to candidacy therapy. On the basis of design, the market is bifurcated into transcutaneous ventricular assist devices and implantable ventricular assist devices. By age, the market is divided into adults and pediatrics. Region-wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, North Africa, Middle East & Africa).
The key players that operate in the ventricular assist devices market are Abbott Laboratories, Abiomed, Inc., AdjuCor GmbH, Berlin Heart GmbH, Bivacor Inc., Calon Cardio-Technology Ltd, Carmat SA, CH Biomedical, Inc., Corewave SA, Evaheart, Inc., Fineheart, Jarvik Heart, Inc., LivaNova PLC, NuPulseCV, Inc., SynCardia Systems, LLC, and Windmill Cardiovascular Systems. The key players have adopted product launch, product development, and product approval as the key strategies to strengthen their foothold in the competitive market.
Increase in incidences of heart failures is the major factor driving the growth of ventricular assist devices market. There is increase in heart failure cases around the globe owing to various factors such as high prevalence of chronic conditions such as hypertension, diabetes, and obesity. Moreover, factors such as poor lifestyle choices and environmental pollution along with increased stress levels contribute to increase in the number of heart failure cases. For instance, according to an article published by Centers for Diseases Control and Prevention (CDC), in January 2023, heart disease is the leading cause of death for both men and women in the U.S. and about 6.2 million adults in the U.S. have heart failure. Thus, high incidences of heart failure increases the demand for ventricular assist devices around the globe and thus propels the growth of the market.
In addition, one of the major driving factors of the global ventricular assist devices market is the high prevalence of conditions such as diabetes, atherosclerosis, strokes, hypertension, and other chronic disorders. These conditions mainly arise due to change in lifestyle habits, unhealthy dietary habits, lack of physical activity, and smoking. This further raises the chances of heart failure in the patient and thus increases the demand for ventricular assist devices. Hence, such factors are expected to boost the growth of the market.
The global ventricular assist devices market is segmented into product, application, design, age, and region. By product, the market is categorized into left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs). On the basis of application, the market is fragmented into bridge-to-transplant (BTT), destination therapy, bridge-to-recovery (BTR), and bridge to candidacy therapy. On the basis of design, the market is bifurcated into transcutaneous ventricular assist devices and implantable ventricular assist devices. By age, the market is divided into adults and pediatrics. Region-wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, North Africa, Middle East & Africa).
The key players that operate in the ventricular assist devices market are Abbott Laboratories, Abiomed, Inc., AdjuCor GmbH, Berlin Heart GmbH, Bivacor Inc., Calon Cardio-Technology Ltd, Carmat SA, CH Biomedical, Inc., Corewave SA, Evaheart, Inc., Fineheart, Jarvik Heart, Inc., LivaNova PLC, NuPulseCV, Inc., SynCardia Systems, LLC, and Windmill Cardiovascular Systems. The key players have adopted product launch, product development, and product approval as the key strategies to strengthen their foothold in the competitive market.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ventricular assist devices market analysis from 2023 to 2035 to identify the prevailing ventricular assist devices market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the ventricular assist devices market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global ventricular assist devices market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Application
- Bridge-To-Transplant (BTT)
- Destination Therapy
- Bridge-To-Recovery (BTR)
- Bridge To Candidacy Therapy
By Design
- Transcutaneous Ventricular Assist Devices
- Implantable Ventricular Assist Devices
By Age
- Adults
- Pediatrics
By Product
- Left Ventricular Assist Devices (LVADs)
- Right Ventricular Assist Devices (RVADs)
- Biventricular Assist Devices (BIVADs)
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Evaheart, Inc.
- Abiomed, Inc.
- Abbott Laboratories
- CH Biomedical, Inc.
- Carmat SA
- Bivacor Inc.
- LivaNova PLC
- Berlin Heart GmbH
- Fineheart
- AdjuCor GmbH
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: VENTRICULAR ASSIST DEVICES MARKET, BY PRODUCT
CHAPTER 5: VENTRICULAR ASSIST DEVICES MARKET, BY APPLICATION
CHAPTER 6: VENTRICULAR ASSIST DEVICES MARKET, BY DESIGN
CHAPTER 7: VENTRICULAR ASSIST DEVICES MARKET, BY AGE
CHAPTER 8: VENTRICULAR ASSIST DEVICES MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
According to the report titled, “Ventricular Assist Devices Market," the ventricular assist devices market was valued at $1,338.53 million in 2021, and is projected to reach $2,880.66 million by 2031, growing at a CAGR of 7.9% from 2022 to 2031.Ventricular Assist Devices (VADs) are medical devices designed to support the function of the heart in patients with heart failure. It works by assisting the heart in pumping blood and maintaining blood flow throughout the body. VADs are typically used as a temporary measure to support patients with heart failure while the patient undergoes further treatment, such as heart surgery. They can also be used as a bridge to transplant, allowing patients with heart failure to wait for a heart transplant while still receiving support from a VAD.
Key factors driving the growth of the ventricular assist device market include increase in incidence of heart failures, technological advancements, rise in patient awareness about heart failure treatment options and dearth of heart donors. In addition, growing demand for minimally invasive surgical procedures such as VADs is also driving the growth of the market. VADs are becoming increasingly popular due to their minimally invasive nature and their ability to provide a bridge to transplant or recovery. Compared to traditional open-heart surgeries, VADs can be implanted with a smaller incision and minimal disruption to the surrounding tissues. This further results in a shorter hospital stay, faster recovery, and less pain for the patient having VAD implantation. Moreover, VADs can be used as a bridge to transplantation, allowing patients to recover and wait for a suitable donor heart without undergoing multiple open-heart surgeries. These advantages are contributing to the growing demand for VADs as a treatment option for heart failure which is boosting the growth of ventricular assist devices market.
Factors such as Expansion into new markets and increasing reimbursement policies is anticipated to offer lucrative opportunities for the growth of ventricular assist devices market. There is an increase in reimbursement for ventricular assist devices by the insurance companies, which makes it possible for the people in developing countries to procure the devices. In addition, government programs providing greater financial coverage or reimbursement for these devices is also anticipated to increase the adoption of VADs. This can make it easier for patients to access ventricular assist devices as a treatment option for heart failure, which is estimated to boost the market during the forecast period.
The ventricular assist devices market is segmented on the basis of product, application, design, age, and region. By product, the market is categorized into left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs). On the basis of application, the market is fragmented into bridge-to-transplant (BTT), destination therapy, bridge-to-recovery (BTR), and bridge to candidacy therapy. On the basis of design, the market is bifurcated into transcutaneous ventricular assist devices and implantable ventricular assist devices. By age, the market is divided into adults and pediatrics. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Major Key players that operate in the global ventricular assist devices market are Abbott Laboratories, Abiomed, Inc., AdjuCor GmbH, Berlin Heart GmbH,Bivacor Inc., Calon Cardio-Technology Ltd, Carmat SA, CH Biomedical, Inc., Corewave SA, Evaheart, Inc., Fineheart, Jarvik Heart, Inc., LivaNova PLC, NuPulseCV, Inc., SynCardia Systems, LLC, and Windmill Cardiovascular Systems. The players in the market have been actively engaged in the adoption various strategies such as product upgrade/development, new product development, product approval, clinical trials, and product launch, acquisition and others to remain competitive and gain advantage over the competitors in the market. For instance, in November 2021, CH Biomedical received approval for the implantable CH-VAD left ventricular assist system by the National Medical Products Administration (NMPA) for marketing in China.
Key Market Insights
- By product, the Left Ventricular Assist Devices (LVADs) segment was the highest revenue contributor to the market and is estimated to reach $2298.23 million by 2031, with a fastest rate at a CAGR of 8.3%.
- By application, the Bridge-To-Transplant (BTT) segment dominated the global market. However, the Destination Therapy segment is expected to be the fastest-growing segment with a CAGR of 9.1% during the forecast period.
- Based on design, the Implantable Ventricular Assist Devices segment was the highest revenue contributor to the market and is anticipated to grow at a fastest rate with a CAGR of 8.1% during the forecast period.
- Based on age, the adults segment dominated the market in 2021, and the pediatrics segment is anticipated to grow at a fastest rate during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 11.1% during the forecast period
Companies Mentioned
- Evaheart, Inc.
- Abiomed, Inc.
- Abbott Laboratories
- CH Biomedical, Inc.
- Carmat SA
- Bivacor Inc.
- LivaNova PLC
- Berlin Heart GmbH
- Fineheart
- AdjuCor GmbH
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
